Sub-Navigation

• Investor News
• Ad-hoc Publications
• Archive
  • Overview
  • Investor News 2011
  • Investor News 2010
  • Investor News 2009
  • Investor News 2008
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2011
  • Ad-hoc 2010
  • Ad-hoc 2009
  • Ad-hoc 2008
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Nachhaltigkeit
• Presse
• Bayer in Social Media

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2010

Search

Here you find Investor News of year 2010. Ad-hoc messages issued in year 2010 can be found here.
Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Monday December 20, 2010

For use outside the U.S. only

Bayer and Regeneron Report Positive Results for VEGF Trap-Eye in Central Retinal Vein Occlusion and in Diabetic Macular Edema

In Phase 3 study in CRVO, 56 percent of VEGF Trap-Eye patients gained at least 15 letters of vision compared to 12 percent in control group / In Phase 2 study in DME, patients in all VEGF Trap-Eye dose groups, including VEGF Trap-Eye dosed every two months, maintained or increased vision gains through 52-weeks

Friday December 17, 2010

For use outside the US only

FDA approves Bayer's new oral contraceptive Safyral

Oral contraceptive raises folate levels, reducing the risk of neural tube defects

Monday December 13, 2010

Bayer CropScience and Evogene Sign Collaboration Agreement to Improve Wheat Seed

Focus on yield, drought tolerance and fertilizer use efficiency / Use of both advanced breeding and genetic modification methods

Friday December 10, 2010

For use outside the US only

New oral contraceptive regimen submitted for marketing authorization in the EU

Will support women in managing their menstrual cycle individually / Minimizes the number of bleedings / Innovative device, supporting women to follow an individualized intake regimen

Thursday December 09, 2010

Capital expenditures of EUR 1 billion:

Bayer plans to significantly expand capacities in China

Group sales in Greater China planned to increase to around EUR 5 billion by 2015 / New MaterialScience production plants to be constructed and existing ones expanded /Expansion of research and development activities / Headquarters of the Polycarbonates Business Unit to move to Shanghai

Monday November 22, 2010

Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration

In both studies, all regimens of VEGF Trap-Eye, including VEGF Trap-Eye dosed every two months, achieved primary endpoint compared to ranibizumab dosed every month / Regulatory applications for marketing approval planned in first-half of 2011

Thursday November 18, 2010

More innovation, less administration

Bayer focuses resources on growth and innovation

Major investment necessary in development pipeline, marketing and emerging markets / Annual savings of EUR 800 million planned from 2013 / Planned net reduction of about 2,000 jobs worldwide by the end of 2012

Wednesday November 17, 2010

Planned investment of EUR 110 million:

Bayer MaterialScience increases downstream presence in China

Five new facilities to be completed by 2012

Wednesday November 03, 2010

Bayer to strengthen Animal Health business in Asia Pacific and Latin America

Bayer acquires Animal Health Company Bomac in New Zealand

Complementary portfolios with strong growth opportunities in combining both businesses / Creation of southern hemisphere hub to drive product innovation

Thursday October 28, 2010

Interim report for the third quarter of 2010:

Bayer lifts sales and earnings again

Sales grow by 16.1 percent to EUR 8,581 million / EBITDA before special items up 10.5 percent to EUR 1,656 million / Core earnings per share increase by 21.8 percent to EUR 0.95 / Provisions of EUR 436 million established for litigations / Net financial debt reduced by EUR 1.6 billion to EUR 9.1 billion / Group outlook for 2010 confirmed

Friday October 15, 2010

FOR USE OUTSIDE THE U.S. AND UK ONLY - Multiple Sclerosis:

21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment

Study provides the first and only survival data for any multiple sclerosis (MS) treatment

Monday October 11, 2010

For use outside the US only

EU regulators okay Qlaira® for the treatment of heavy menstrual bleeding

Monday September 27, 2010

For use outside the US only - U.S. approval for a new oral contraceptive:

Bayer receives approval for Beyaz® in the U.S.

First and only contraceptive to raise folate levels, reducing the risk of neural tube defects / First and only FDA-approved birth control pill with four indications

Thursday September 09, 2010

Solutions from sowing to the harvest:

Bayer CropScience plans to further expand business with high-margin products and new crops

Friedrich Berschauer hands over reins to Sandra E. Peterson / New crop protection agents with peak sales potential of more than EUR 1 billion / BioScience Business Unit plans around 18 new products by 2016

Monday September 06, 2010

LEVITRA 10mg Orodispersible Tablet for the Treatment of Erectile Dysfunction approved in Europe

New formulation expected to be launched in November 2010

Wednesday September 01, 2010

Further milestone to strengthen cereal product portfolio:

New fungicidal active ingredient Bixafen registered in the United Kingdom for the first time

Global peak sales potential of about EUR 300 million

Tuesday August 31, 2010

Treatment of Deep Vein Thrombosis:

Bayer's Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study

Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010

Monday August 30, 2010

Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use

Bayer's dermatology subsidiary Intendis prepares to enter aesthetics segment / Joint development of first-in-class injectable drug for minimally invasive facial fat reduction

Wednesday August 04, 2010

Bayer's Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study

Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study / Rivaroxaban well tolerated in this long-term trial / Full data set to be presented at Hot Line Session at ESC 2010

Wednesday August 04, 2010

For use outside the USA only

FDA Accepts New Drug Application for Gadovist® 1.0 Injection in Magnetic Resonance Imaging

Thursday July 29, 2010

MaterialScience leaves the crisis behind

Bayer increases sales and earnings in the second quarter

Sales grow by 14.6 percent to EUR 9,179 million / EBITDA before special items up 8.6 percent to EUR 1,917 million / Core earnings per share increase by 9.5 percent to EUR 1.15 / Investing in the future: research and development expenses in 2010 to reach a new high of approximately EUR 3.1 billion / Group outlook confirmed for 2010

Thursday July 15, 2010

New rice fungicide isotianil granted regulatory approval in Japan

Routine® already successfully launched in Korea

Monday June 21, 2010

New erectile dysfunction treatment STAXYN

Orodispersible formulation of Levitra® (vardenafil HCI) soon available

Thursday June 17, 2010

Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics

Collaboration Focuses on the Discovery and Development of Multiple Antibody, Protein and Small Molecule Agents Targeting the Wnt Pathway

Thursday June 17, 2010

Results from Phase III EINSTEIN-DVT Study with Bayer's Rivaroxaban to be Presented at Hot Line Session at ESC 2010

Tuesday June 15, 2010

Bayer sues Teva and Barr for false advertising and patent infringement in connection with Teva's generic oral contraceptive Gianvi

Gianvi

Monday June 14, 2010

Phase III Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival

Positive Secondary Endpoint of Progression Free Survival / Clinical Trial Program in Lung Cancer Ongoing

Thursday May 20, 2010

New choices for cotton growers:

Bayer CropScience and Dow AgroSciences sign global cotton technology cross-licensing agreements

Tuesday May 18, 2010

American Thoracic Society (ATS) Congress 2010, New Orleans, USA:

Bayer Presents New Riociguat Phase II Data

First Phase II study in patients with pulmonary hypertension owing to interstitial lung disease meets primary objectives / First long-term extension data of Phase II study in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension show sustained improvement in exercise capacity

Friday May 14, 2010

Bayer MaterialScience raises prices for polyurethane raw materials

Friday May 07, 2010

US approval for the indication pregnancy prevention:

Bayer receives approval for its new oral contraceptive in the U.S.

The first and only contraceptive to bring estradiol valerate together with dienogest in a new dosing regimen / Product will be marketed as Natazia® in the U.S.

Friday May 07, 2010

Bayer Schering Pharma Initiates Phase III Trial of Regorafenib in Metastatic Colorectal Cancer

Wednesday May 05, 2010

Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement for the Development and Commercialization of Treatment for Vaginal Atrophy and Female Sexual Dysfunction

Friday April 30, 2010

CEO Werner Wenning at the Annual Stockholders' Meeting of Bayer AG:

"We plan to grow again"

2009 operationally a strong year in a difficult environment / Bayer stock performance in 2009: plus 40 percent / Proposal to pay an unchanged dividend of EUR 1.40 per share for 2009 / Strong gains in sales and earnings in the first quarter of 2010 / Personnel changes on the Board of Management and the Supervisory Board

Thursday April 29, 2010

Interim report for the first quarter of 2010:

Bayer achieves strong gains in sales and earnings

Sales advance by 5.3 percent to EUR 8,316 million / EBITDA before special items climbs by 13.2 percent to EUR 1,918 million / Net income up 63.1 percent to EUR 693 million / Core earnings per share increase by 31.9 percent to EUR 1.20 / Group outlook raised for 2010

Tuesday April 27, 2010

Sandra E. Peterson appointed new Chairman of the Board of Management of Bayer CropScience

Current Chairman Prof. Friedrich Berschauer to retire / Achim Noack appointed to the Board of Management of Bayer CropScience / Dr. Dirk Van Meirvenne to be Managing Director of Bayer Technology Services

Wednesday April 21, 2010

Leadership change effective August 15, 2010:

Dr. Jörg Reinhardt appointed new CEO of Bayer HealthCare

Arthur Higgins to leave the company at the end of April / Dr. Marijn Dekkers to head the subgroup temporarily as of May 1

Monday April 19, 2010

Bayer CropScience: verdict in Arkansas biotech rice trial incomprehensible

Company acted responsibly and appropriately at all times

Friday March 26, 2010

CHMP's Pharmacovigilance Working Party completes review:

Bayer will update Yasmin® label in the EU

Positive benefit/risk profile of Yasmin® confirmed

Wednesday March 10, 2010

MR contrast agents for diagnosis of breast cancer

Bayer starts Phase III study to evaluate efficacy and safety of Gadovist® in magnetic resonance mammography

Monday March 01, 2010

Approval process begins in April 2010:

Bayer MaterialScience planning new world-scale TDI plant at Dormagen site

EUR 150 million investment in the future / New production process was developed in Dormagen / Energy savings of up to 60 percent versus conventional plants

Friday February 26, 2010

Bayer modifies Board of Management compensation system

Reduction of short-term incentive and strengthening of long-term compensation component / Extended share retention period under long-term incentive program / Increased personal investment in Bayer stock / Adjustments effective January 1, 2010 / Compensation system to be submitted to Annual Stockholders' Meeting for approval

Friday February 26, 2010

2009: operationally one of the strongest years - optimism for the future

Bayer successful in a difficult environment

Group sales EUR 31,168 million (minus 5.3 percent) / EBITDA before special items EUR 6,472 million (minus 6.6 percent) / Net income EUR 1,359 million (minus 20.9 percent) / Net cash flow significantly improved to EUR 5,375 million (plus 49 percent) / Net financial debt reduced by EUR 4.5 billion to EUR 9.7 billion / Core earnings per share expected to improve by about 10 percent in 2010

Wednesday February 24, 2010

Bayer proposes dividend for 2009 of EUR 1.40 per share

Thursday February 18, 2010

VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema

Statistically significant improvement in vision achieved over 24 weeks / Results to be presented at the Angiogenesis 2010 - Clinical Trials meeting in Miami, Florida on February 20, 2010

Monday January 25, 2010

Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis

Study will not be able to meet primary endpoint / Bayer remains committed to developing its long-acting recombinant factor VIII compounds; alternative candidates in development